COVID-19 and seasonal influenza
Conditions
Interventions
None listed
Sponsors
Takeda Pharmaceutical Company Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [COVID-19] [1]. Having confirmed diagnosis of COVID-19 defined by a coding system of international Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10 code) [U071, U072, B342] at least one from June 2023 to April 2025. Diagnosis without suspicion flag will be targeted. [2]. Having specific SARS-CoV-2 detection test defined by the billing code or procedure code for the COVID-19 in the same month or the previous month as the diagnosis of COVID-19 detected at criteria [1]. [Seasonal influenza] [1]. Having diagnosis of seasonal influenza defined by ICD-10 code [J09, J10, J11] at least one after June 2023 to April 2025. Diagnosis without suspicion flag will be targeted. [2]. Having specific detection test defined by the billing code or procedure code for the seasonal influenza in the same month or the previous month as the diagnosis of seasonal influenza detected at criteria [1].
Exclusion criteria
Exclusion criteria: Patients with either COVID-19 or seasonal influenza must not meet any of the following criteria. [1]. Available baseline period obtained by the ledger information is less than three months. [2]. The index date of COVID-19 and seasonal influenza are identified in the same month. [3]. For COVID-19 patients, the patients have confirmed COVID-19 diagnosis exists during the baseline period. [4]. For seasonal influenza patients, the patients have confirmed seasonal influenza diagnosis exists during the baseline period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospitalization | — |
Countries
Japan
Contacts
Public ContactKiyoto Naito
Takeda Pharmaceutical Company Limited Japan Medial Office
Outcome results
None listed